Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Need the batch documentation before you order
BPC-157 does not cause traditional tolerance or require post-cycle therapy like hormonal compounds
As levels drop, inflammation can become more chronic and harder to manage
A.SwantonC.SeidenM
BPC-157 supports connective tissue through periods of strain and then helps the body reset overnight
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
US$ 29.90
US$ 21.36
US$ 27.64
US$ 27.92
US$ 21.89
